These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 39029155)

  • 1. Targeting tumour metabolism in melanoma to enhance response to immune checkpoint inhibition: A balancing act.
    Tiersma JF; Evers B; Bakker BM; Reijngoud DJ; de Bruyn M; de Jong S; Jalving M
    Cancer Treat Rev; 2024 Sep; 129():102802. PubMed ID: 39029155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the vascular endothelial growth factor receptor-1 by the monoclonal antibody D16F7 to increase the activity of immune checkpoint inhibitors against cutaneous melanoma.
    Lacal PM; Atzori MG; Ruffini F; Scimeca M; Bonanno E; Cicconi R; Mattei M; Bernardini R; D'Atri S; Tentori L; Graziani G
    Pharmacol Res; 2020 Sep; 159():104957. PubMed ID: 32485280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Entering the TiME machine: How age-related changes in the tumor immune microenvironment impact melanoma progression and therapy response.
    Carey AE; Weeraratna AT
    Pharmacol Ther; 2024 Oct; 262():108698. PubMed ID: 39098769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.
    Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H
    Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceramide metabolism alterations contribute to Tumor Necrosis Factor-induced melanoma dedifferentiation and predict resistance to immune checkpoint inhibitors in advanced melanoma patients.
    Dufau C; Genais M; Mucher E; Jung B; Garcia V; Montfort A; Tosolini M; Clarke CJ; Medin JA; Levade T; Delord JP; Meyer N; Pancaldi V; Andrieu-Abadie N; Ségui B
    Front Immunol; 2024; 15():1421432. PubMed ID: 39136013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding the Tumor Microenvironment in Melanoma Patients with In-Transit Metastases and Its Impacts on Immune Checkpoint Immunotherapy Responses.
    Tian J; Quek C
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive biomarkers of response to immune checkpoint inhibitors in melanoma.
    Nebhan CA; Johnson DB
    Expert Rev Anticancer Ther; 2020 Feb; 20(2):137-145. PubMed ID: 31997676
    [No Abstract]   [Full Text] [Related]  

  • 8. Myeloid-T cell interplay and cell state transitions associated with checkpoint inhibitor response in melanoma.
    Schlenker R; Schwalie PC; Dettling S; Huesser T; Irmisch A; Mariani M; Martínez Gómez JM; Ribeiro A; Limani F; Herter S; Yángüez E; Hoves S; Somandin J; Siebourg-Polster J; Kam-Thong T; de Matos IG; Umana P; Dummer R; Levesque MP; Bacac M
    Med; 2024 Jul; 5(7):759-779.e7. PubMed ID: 38593812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of an IFNγ response-related signature for predicting the survival of cutaneous melanoma.
    Hu B; Wei Q; Li X; Ju M; Wang L; Zhou C; Chen L; Li Z; Wei M; He M; Zhao L
    Cancer Med; 2020 Nov; 9(21):8186-8201. PubMed ID: 32902917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Abscopal Effect in the Era of Checkpoint Inhibitors.
    Kodet O; Němejcova K; Strnadová K; Havlínová A; Dundr P; Krajsová I; Štork J; Smetana K; Lacina L
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Checkpoint Inhibitor Therapy for Metastatic Melanoma: What Should We Focus on to Improve the Clinical Outcomes?
    Hossain SM; Ly K; Sung YJ; Braithwaite A; Li K
    Int J Mol Sci; 2024 Sep; 25(18):. PubMed ID: 39337605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Normalization Cancer Immunotherapy for Melanoma.
    Vesely MD; Chen L
    J Invest Dermatol; 2020 Jun; 140(6):1134-1142. PubMed ID: 32092349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mapping the single cell spatial immune landscapes of the melanoma microenvironment.
    Magrill J; Moldoveanu D; Gu J; Lajoie M; Watson IR
    Clin Exp Metastasis; 2024 Aug; 41(4):301-312. PubMed ID: 38217840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis.
    Erkes DA; Cai W; Sanchez IM; Purwin TJ; Rogers C; Field CO; Berger AC; Hartsough EJ; Rodeck U; Alnemri ES; Aplin AE
    Cancer Discov; 2020 Feb; 10(2):254-269. PubMed ID: 31796433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MYC oncogene is associated with suppression of tumor immunity and targeting Myc induces tumor cell immunogenicity for therapeutic whole cell vaccination.
    Wu X; Nelson M; Basu M; Srinivasan P; Lazarski C; Zhang P; Zheng P; Sandler AD
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33757986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The tumour immune landscape and its implications in cutaneous melanoma.
    Attrill GH; Ferguson PM; Palendira U; Long GV; Wilmott JS; Scolyer RA
    Pigment Cell Melanoma Res; 2021 May; 34(3):529-549. PubMed ID: 32939993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The immune tumour microenvironment of neuroendocrine tumours and its implications for immune checkpoint inhibitors.
    Takkenkamp TJ; Jalving M; Hoogwater FJH; Walenkamp AME
    Endocr Relat Cancer; 2020 Sep; 27(9):R329-R343. PubMed ID: 32590336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of exercise and anti-PD-1 on the tumour microenvironment.
    Buss LA; Williams T; Hock B; Ang AD; Robinson BA; Currie MJ; Dachs GU
    Immunol Lett; 2021 Nov; 239():60-71. PubMed ID: 34480981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis.
    Versluis JM; Hendriks AM; Weppler AM; Brown LJ; de Joode K; Suijkerbuijk KPM; Zimmer L; Kapiteijn EW; Allayous C; Johnson DB; Hepner A; Mangana J; Bhave P; Jansen YJL; Trojaniello C; Atkinson V; Storey L; Lorigan P; Ascierto PA; Neyns B; Haydon A; Menzies AM; Long GV; Lebbe C; van der Veldt AAM; Carlino MS; Sandhu S; van Tinteren H; de Vries EGE; Blank CU; Jalving M
    Eur J Cancer; 2021 Jul; 151():72-83. PubMed ID: 33971447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advancing immunotherapy for melanoma: the critical role of single-cell analysis in identifying predictive biomarkers.
    He R; Lu J; Feng J; Lu Z; Shen K; Xu K; Luo H; Yang G; Chi H; Huang S
    Front Immunol; 2024; 15():1435187. PubMed ID: 39026661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.